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Abstract
Background Miriplatin (formerly SM-11355), a novel
lipophilic platinum complex developed to treat hepatocellu-
lar carcinoma, is administered into the hepatic artery using
an oily lymphographic agent (Lipiodol Ultra-Fluide®) as a
carrier. We clariWed the usefulness of miriplatin as an agent
for transarterial chemoembolization.
Methods Platinum compounds released from miriplatin
into serum, medium and Earle’s balanced salt solution were
examined. Then, miriplatin and cisplatin were administered
to rats bearing hepatoma AH109A tumors in livers. Plati-
num concentrations in tissues and DNA were assessed.
Results Miriplatin showed a more sustained release than
cisplatin. Dichloro[(1R, 2R)-1, 2-cyclohexane diamine-N,
N]platinum, the most abundant platinum compound
released from miriplatin, was as eVective as cisplatin in
inhibiting the growth of cells. Miriplatin was selectively
disposed of in tumors, maintained in tumors longer than
cisplatin and caused apparent tumor regression inducing
platinum-DNA adducts to form and massive apoptosis.
Conclusion Miriplatin appears to be a suitable chemo-
therapeutic agent for transarterial chemoembolization.
Keywords Miriplatin · Lipiodol · 
Platinum-DNA adducts · Apoptosis · 
Hepatocellular carcinoma
Introduction
Hepatocellular carcinoma (HCC) is one of the most com-
mon cancers, and its incidence is increasing worldwide due
to the dissemination of hepatitis B and C virus infection
[1–3]. It is clear that the most powerful risk factor is liver
cirrhosis associated with a viral infection or high alcohol
intake. Approximately 80% of Japanese HCC patients are
diagnosed with hepatitis C virus (HCV)-associated cirrho-
sis or chronic hepatitis. Once cirrhosis is established, HCC
develops at an annual rate of 1–7% [4, 5], although inter-
feron therapy reduces the incidence of HCC among patients
with HCV-related cirrhosis or chronic hepatitis [6–8]. Sur-
veillance and advances in imaging have made early diagno-
sis possible. However, the prognosis is poor because
surgical resection, liver transplantation, or percutaneous
ablation is applicable to only a small proportion of patients,
while most patients with HCC are diagnosed at the interme-
diate to advanced stage.
The liver receives a dual blood supply from the hepatic
artery and the portal vein, whereas HCC is fed by only the
hepatic artery [9–11]. On the basis of this peculiar feature
of HCC, the eYcacy and tumor selectivity of antitumor
agents can be increased by injecting embolic material or the
oily lymphographic agent (Lipiodol Ultra-Fluide®, LPD)
through the hepatic artery. LPD is known to be selectively
distributed and retained for a long period in hepatic tumor
tissues after intra-hepatic arterial injection [12–15]. Several
antitumor agents such as cisplatin, doxorubicin, epirubicin,
mitomycin C, and zinostatin stimalamer, suspended or
emulsiWed in LPD, have been clinically studied [16–23].
Zinostatin stimalamer has been used for primary unresec-
table HCC as an approved agent in Japan since 1994 [19,
20]. It is used as a suspension in LPD, given by arterial
administration via the hepatic artery. Cisplatin suspended in
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LPD (cisplatin/LPD) has been reported to selectively accu-
mulate in the HCC, and gradually release platinum after
intra-hepatic arterial administration [17,  18]. However,
there is still no standard transarterial chemoembolization
(TACE) for patients with unresectable HCC. As most of the
antitumor agents used for TACE are water-soluble, we have
investigated a lipophilic platinum complex which utilizes
LPD as the carrier solvent. Antitumor platinum complexes
undergo leaving group exchange prior to the reaction with
DNA in tumors, while, in physiological surroundings, any
leaving groups are easily displaced by biological nucleo-
philes such as sulfur-containing amino acids, glutathione,
and proteins, leading to inactivation [24,  25]. Therefore,
platinum complexes containing lipophilic leaving groups
are expected to be soluble or easily suspended in LPD, and
be gradually released and active only at the tumor site,
reducing systemic toxicity due to low circulation after
intra-hepatic arterial administration.
Miriplatin (formerly SM-11355), (SP-4-2)-[(1R,2R)-
cyclohexane-1,2-diamine-N,N]bis (tetradecanoato-O)plati-
num, is one of the lipophilic platinum complexes synthesized
by Maeda et al. [26], which can be easily suspended in LPD
and release active platinum compounds into the aqueous
phase gradually [27,  28]. Miriplatin suspended in LPD
(miriplatin/LPD) had antitumor eVects on hepatic tumors
after intra-hepatic arterial administration in several animal
models [27, 29, 30]. In vitro studies have shown that plati-
num compounds released from miriplatin/LPD were incor-
porated into rat hepatoma cells including cisplatin-resistant
cells, and form platinum-DNA adducts [31, 32]. However,
it has not been fully evaluated whether the sustained release
of active platinum compounds from miriplatin/LPD could
contribute the tumor-selective delivery, and whether the
formation of platinum-DNA adducts by miriplatin could
lead to tumor regression. In this study, conWrming that
miriplatin/LPD was active and retained in rat hepatic
tumors after intra-hepatic arterial administration, we exam-
ined in vivo antitumor activities of miriplatin, cisplatin, and
zinostatin stimalamer at the therapeutic dose of each agent.
To further investigate which mechanism causes tumor
regression after miriplatin treatment, we examined the
formation of platinum-DNA adducts and induction of
apoptosis in rat hepatic tumors.
Materials and methods
Chemicals
Miriplatin, dichloro[(1R,2R)-1,2-cyclohexanediamine-N,N]
platinum (DPC), chloro[(1R,2R)-1,2-cyclohexanediamine-
N,N]iodo platinum (DPCI) and [(1R,2R)-1,2-cyclohexane-
diamine-N,N]diiodo platinum (DPI) were prepared by
Dainippon Sumitomo Pharma Co., Ltd (Osaka, Japan). Cis-
platin was obtained from Nihon Kayaku Co., Ltd (Tokyo,
Japan) or SIGMA (St. Louis, MO). Zinostatin stimalamer
and Lipiodol Ultra-Fluide® (Guerbet) were from Astellas
Pharma Inc. (Tokyo, Japan) and TERUMO Corp. (Tokyo,
Japan), respectively.
Cell line and animals
The rat ascite hepatoma cell line AH109A was provided by
Kumamoto University (Kumamoto, Japan). For in vitro
use, AH109A cells taken from ascites of male Donryu rats
(Charles Liver Laboratories, Japan) were grown in RPMI
1640 medium supplemented with antibiotics (penicillin and
streptomycin) and 10–20% heat-inactivated fetal bovine
serum (FBS). Cells were cultured at 37°C in 5% CO2. To
establish the hepatic tumor model previously reported by
Kishimoto et al. [29], AH109A cells originally taken from
ascites of male Donryu rats were transplanted subcutane-
ously in rats. Subcutaneous tumors resected (approximately
1 £ 1 £ 1 mm cubes) were transplanted into the subcapsu-
lar parenchyma of the liver. The hepatic tumor model was
maintained by repeated transplantation into the rat liver.
The care and treatment of experimental animals were in
accordance with institutional guidelines.
In vitro release of platinum compounds into rat serum
Miriplatin was easily suspended at 20 mg/mL by adding
LPD and shaking. One milliliter of miriplatin/LPD and cis-
platin/LPD (20 mg/mL) were layered over 12 mL of rat
serum in test tubes. Test tubes were rotated vertically for
7 days at 5 rpm in an incubator at 37°C under protection
from light [28]. The aqueous phase was obtained by centri-
fuging test tubes at 1,200 rpm for 30 min at room tempera-
ture. The platinum concentrations in serum after additional
centrifuging at 12,000 rpm for 90 min at room temperature
were quantitatively analyzed at 265.9 nm by Xameless
atomic absorption spectrometry (FAAS) Z-9000 (HITACHI,
Tokyo, Japan).
In vitro release of platinum compounds into Earle’s 
balanced salt solution
Three milliliters of miriplatin/LPD (20 mg/mL) was lay-
ered over 6 mL of Earle’s balanced salt solution (Invitrogen
Corp.) supplemented with magnesium sulfate at 97 mg/L in
test tubes [33]. Test tubes were rotated vertically for 7 days
at 5 rpm in an incubator at 37°C under protection from light
[28]. The aqueous phase was obtained by centrifuging test
tubes at 1,200 rpm for 30 min at room temperature. Plati-
num compounds in the aqueous phase after additional
centrifuging at 12,000 rpm for 30 min at room temperatureCancer Chemother Pharmacol (2009) 64:473–483 475
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were analyzed by high performance liquid chromatography
(HPLC). Samples (100 L) were loaded on a 2.1 £
100 mm reverse phase column, XTerra MS C18 packed
with 3.5-m particles (Waters, Milford, MA, USA), and
eluted at 40°C with 10% acetonitrile at a Xow rate of
0.3 mL/min. Fractions from the reverse phase column were
analyzed on-line with an inductively coupled plasma mass
spectrometer (ICP-MS), Agilent 7500s (Agilent Technolo-
gies, Santa Clara, CA, USA), for the detection of platinum.
In vitro cell proliferation assay
Aliquots of AH109A cells were plated into 24-well micro-
plates. Following cell adherence (1 day), LPD alone and
agents suspended in LPD were added to Falcon cell culture
inserts (Becton Dickinson and Company, Franklin Lakes,
NJ, USA), equipped with a 0.4-m pore membrane on their
bottom. After 7 days of incubation at 37°C in 5% CO2, the
numbers of viable cells were examined using AlamarBlue
(Trek diagnostic systems, Westlake, OH, USA). The IC50
value was deWned as the concentration inhibiting cell
growth by 50% compared with treatment with LPD alone.
To examine platinum concentrations in the medium, agents
suspended in LPD were added to Falcon cell culture inserts
in wells containing the culture medium alone. The platinum
concentrations were quantitatively analyzed by FAAS.
Alternatively, aliquots of AH109A cells were plated into
96-well microplates. Following cell adherence (1 day),
agents in aqueous solution were added. After 3 days of
incubation at 37°C in 5% CO2, the numbers of viable cells
were examined using AlamarBlue.
Blood supply to implanted tumors
Tumor-bearing rats were anesthetized with an injection of
sodium pentobarbital before laparotomy, and a 100% (w/v)
barium sulfate suspension (Kaigen Inc, Osaka, Japan) was
injected into the hepatic artery or the portal vein at the vol-
ume of 0.5 mL/head or 5.0 mL/head, respectively. For
intra-hepatic arterial administration, a catheter with an
inner and outer diameter of 0.28 and 0.61 mm, respectively,
was inserted retrogressively into the gastroduodenal artery
with the tip close to the origin of the proper hepatic artery
[29]. Immediately after the administration, livers were
resected, Wxed in formalin, and radiographed with SRO-
M50 soft X-ray machine (Sofron, Tokyo, Japan).
Distribution of LPD and measurement of platinum 
concentrations in rat livers
Miriplatin/LPD and cisplatin/LPD (400 g/head) were
injected into the hepatic artery of tumor-bearing rats at the
volume of 0.02 mL/head. Immediately and 7 days after the
administration, resected livers were radiographed with a
soft X-ray machine and then divided into tumor tissues and
normal liver tissues. Tissue homogenates incinerated using
nitric acid and hydrogen peroxide were dissolved in 4%
aqua regia and subjected to FAAS [34].
In vivo assay of the growth of tumors implanted in rat livers 
after the intra-arterial administration
Rats bearing a tumor approximately 100–250 mm2 in area
were randomly allocated into diVerent treatment groups and
a control group, each of which consisted of seven rats.
Tumor diameters were measured with calipers, and esti-
mated tumor area was calculated by the formula: (smaller
diameter) £ (larger diameter). All agents suspended in
LPD and LPD alone were injected into the hepatic artery of
tumor-bearing rats at the volume of 0.02 mL/head. The
therapeutic dose of each agent was deWned in this study as
follows: miriplatin (400 g/head, 20 mg/mL in LPD)
[35,  36], cisplatin (400 g/head, 20 mg/mL) [17] and
zinostatin stimalamer (20 g/head, 1 mg/mL) [19,  20].
After the intra-hepatic arterial administration, the gastrodu-
odenal artery and abdomen were closed with uninterrupted
sutures. The tumor growth rate (%) was calculated with the
following formula: A7/A0 £ 100, where A7 is the estimated
tumor area at day 7 and A0 is the estimated tumor area at
the initiation of the treatment (day 0). The systemic toxicity
of the treatments was assessed in terms of changes in body
weight during the experiments. These were calculated as
(W7 ¡ W0)/W0 £ 100 where W7 is body weight at day 7 and
W0 is body weight at day 0.
Platinum-DNA adducts within cultured cells and tumors 
implanted in rat livers
DNA was isolated from cells or homogenized tumors using
DNAzol reagent (Invitrogen Corp., Carlsbad, CA, USA) in
accordance with the manufacturer’s protocol. After puriWed
DNA was solubilized in Tris-buVered EDTA, the amount
of platinum in DNA was determined by FAAS. The DNA
content was assessed Xuorometrically using Hoechst
33258.
Induction of apoptosis within cultured cells and tumors 
implanted in rat livers
The apoptosis of cells was assessed as the fraction with
sub-G1 DNA content. Cells were Wxed in 80% ethanol for
20 min at room temperature. Following treatment with
1 mg/mL RNase A for 20 min at 37°C, cells were stained in
propidium iodide solution (50 g/mL in 0.1% sodium cit-
rate and 0.1% Triton X-100) and then analyzed using FAC-
Scan  Xow cytometer (Becton Dickinson and Company).476 Cancer Chemother Pharmacol (2009) 64:473–483
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The apoptosis in resected liver in situ was visualized using
the terminal deoxynucleotidyl transferase-mediated dUTP-
biotin nick end labeling assay (Chemicon International Inc.,
Temecula, CA, USA) in accordance with the manufac-
turer’s protocol.
Statistical analysis
DiVerences in tumor growth rates or changes in body
weight between the control group and the treated group
were statistically analyzed by using the Dunnett test
(P < 0.05, two-sided).
Results
In vitro release of platinum compounds from miriplatin/
LPD
To conWrm that miriplatin utilizes LPD as a carrier solvent
leading to long-lasting release, the amounts of platinum
released from miriplatin/LPD in rat serum were compared
with those released from cisplatin/LPD (Fig. 1). While the
amount in serum treated with miriplatin/LPD was 54 § 3 g
after 7 days, cisplatin/LPD released 9,400 § 100 g of plat-
inum in serum within a day. Thus, miriplatin/LPD showed
a more sustained release over 7 days than cisplatin/LPD in
this system using rat serum.
In vitro cell growth inhibition by platinum compounds 
released from miriplatin/LPD
The release characteristics for miriplatin/LPD and cis-
platin/LPD using cell culture inserts are shown in Fig. 2a.
While the platinum concentrations in the medium treated
with miriplatin/LPD gradually increased, depending on
incubation time, for 7 days, cisplatin/LPD caused a rapid
increase in the platinum concentrations in the medium
within a day, with the concentration almost the same until
day 7. Thus, miriplatin/LPD showed a more sustained
release over 7 days than cisplatin/LPD. First, we exam-
ined in vitro antitumor eVects of miriplatin/LPD and cis-
platin/LPD using cell culture inserts. In this system, the
LPD suspension does not make contact with the cells
directly, but via membranes with tiny pores. IC50 values
for rat ascite hepatoma AH109A cells after 7 days of
exposure to miriplatin/LPD and cisplatin/LPD were
0.89 § 015 and 0.14 § 0.09 g/mL, respectively. Increas-
ing the concentrations of miriplatin and cisplatin in LPD
increased the platinum concentrations in medium at day 7
(Fig. 2b). In addition, both agents inhibited cell growth
depending on their concentrations in the medium. Antitu-
mor platinum complexes undergo leaving group exchange
prior to biotransformation. To determine which platinum
compounds were generated from miriplatin/LPD, we
examined those released into Earle’s balanced salt solu-
tion. This solution consists of inorganic ingredients simi-
lar to a culture medium or serum, but lacks glutathione,
amino acids, and proteins which inactivate platinum com-
plexes [33]. Figure 2c shows a representative chromato-
gram. After 7 days, only three platinum complexes; DPC,
DPCI, and DPI were detected in aqueous solution. DPC
was the most abundant of the three. These results show
that biological nucleophiles including chloride can dis-
place leaving groups of miriplatin at concentrations which
occur in the culture medium or serum. Next, in vitro anti-
tumor eVects of miriplatin, cisplatin, and zinostatin sti-
malamer were examined in addition to those of DPC or
DPI, both of which were detected as compounds released
from miriplatin/LPD. IC50 values for AH109A cells after
3 days of exposure to DPC, DPI, cisplatin, and zinostatin
stimalamer were 0.14 § 0.07, 0.83 § 0.32, 0.30 § 0.07,
and 0.13 § 0.00 g/mL, respectively. Miriplatin did not
inhibit cell growth at the highest concentrations tested
(20 g/mL) probably due to its low water solubility. DPC
was about six times more active than DPI, and as potent as
cisplatin and zinostatin stimalamer (Fig. 3). From these
results, it was shown that platinum compounds released
from miriplatin/LPD, but not miriplatin itself, inhibited
the growth of AH109A cells.
Fig. 1 In vitro release of platinum from miriplatin/LPD and cisplatin/
LPD. The amount of platinum released from miriplatin/LPD and cis-
platin/LPD in rat serum. One milliliter of miriplatin/LPD (20 mg/mL,
Wlled square) or cisplatin/LPD (20 mg/mL, open square) was layered
over 12 mL of rat serum in test tubes. Test tubes were rotated vertically
at 5 rpm in an incubator at 37°C under protection from light. The
amounts of platinum in serum and LPD were measured at 265.9 nm
using FAAS. All results are given as the mean § SD (n =3 )
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Formation of platinum-DNA adducts and induction 
of apoptosis in cells
Antitumor platinum complexes have growth inhibitory
eVects on cancer cells by causing platinum-DNA adducts to
form, and apoptotic cell death [37, 38]. The amount of plat-
inum in DNA was used as an overall measure of the forma-
tion of platinum-DNA adducts. After AH109A cells were
treated with miriplatin/LPD (100 g/mL) and cisplatin/
LPD (15 g/mL) for 3 days, 509 § 100 and 34.1 § 11.0 pg
of platinum were incorporated into 1 g of DNA, respec-
tively. Miriplatin/LPD formed more platinum-DNA adducts
than cisplatin/LPD at equitoxic concentrations. To compare
the ability of miriplatin/LPD and cisplatin/LPD to induce
apoptosis, we next evaluated the dose-dependent develop-
ment of apoptosis in AH109A cells by measuring the popu-
lation of sub-G1 apoptotic cells by Xow cytometric analysis
(Fig. 4a). As shown in Fig. 4b, there was a dose-dependent
induction of apoptosis with both agents. Miriplatin/LPD,
like cisplatin/LPD, showed the formation of platinum-DNA
adducts and induction of apoptosis in AH109A cells. Both
platinum-DNA adducts and apoptosis were also observed
in cells treated with DPC or cisplatin as an aqueous solution
for 3 days (data not shown).
Fig. 2 In vitro cell growth inhibition by platinum compounds
released from miriplatin/LPD. a Release characteristics of miriplatin/
LPD and cisplatin/LPD into the culture medium. Aliquots (0.5 mL) of
miriplatin/LPD (100 g/mL, Wlled circle) and cisplatin/LPD (100 g/mL,
open circle) were added into Falcon cell culture inserts in wells
containing 0.5 mL of RPMI 1640 medium supplemented with 10%
FBS. The platinum concentrations in the medium were measured
using FAAS. All results are given as the mean § SD (n = 3 or 6). b The
relation between platinum concentrations in the medium and cytotoxic
activities following treatment with miriplatin/LPD and cisplatin/LPD.
One day after the plating of cells into microplates, miriplatin/LPD and
cisplatin/LPD were added into Falcon cell culture inserts. Cells were
exposed to agents for 7 days at 37°C in 5% CO2. The platinum con-
centration was measured using FAAS. Wlled circle growth rates of
cells treated with miriplatin, open circle growth rates of cells treated
with cisplatin, Wlled square platinum concentrations in the medium
after treatment with miriplatin, open square platinum concentrations
in the medium after treatment with cisplatin. All results are given as
the mean § SD of triplicates. c HPLC/ICP-MS analysis of platinum
compounds released from miriplatin/LPD. Three milliliters of miripl-
atin/LPD (20 mg/mL) was layered over 6 mL of Earle’s balanced salt
solution supplemented with magnesium sulfate in test tubes. Test
tubes were rotated vertically for 7 days at 5 rpm in an incubator at
37°C under protection from light. Platinum compounds in aqueous
phase were analyzed by HPLC/ICP-MS
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stimalamer. All results are given as the mean § SD of triplicates478 Cancer Chemother Pharmacol (2009) 64:473–483
123
Blood supply to tumors, distribution of LPD, and platinum 
concentrations in rat livers
The liver receives a dual blood supply from the hepatic
artery and the portal vein, whereas HCC is fed by only the
hepatic artery [9–11]. To study the blood supply of
AH109A tumors implanted in rat liver, a barium sulfate
suspension was injected into the hepatic artery or the portal
vein. The suspension injected into the portal vein distrib-
uted in non-tumor region, but not in the tumor, while that
injected into the hepatic artery was selectively distributed
in the tumor (Fig. 5a). LPD is known to be selectively dis-
tributed and retained for a long period in hepatic tumor tis-
sues after intra-hepatic arterial injection [12–15]. When
miriplatin/LPD was administered into the hepatic artery,
LPD detected as white dots in the soft X-ray photograph
was selectively retained in tumors, while it disappeared
from non-tumor regions within 7 days (Fig. 5b). A similar
distribution of LPD was observed when cisplatin/LPD and
LPD alone were used (data not shown). Accordingly, the
AH109A tumors implanted in rat livers were supplied
exclusively by the hepatic artery, and LPD with or without
agents administered into the hepatic artery could be selec-
tively retained in tumors of rats. To examine whether
miriplatin is retained in tumors by utilizing LPD as a
tumor-selective carrier, the platinum concentrations in
tissues were measured immediately and 7 days after the
intra-hepatic arterial administration of miriplatin/LPD and
cisplatin/LPD (Fig. 5c). The platinum concentrations in
AH109A tumors were higher than those in non-tumor
regions on both days, irrespective of the agents. On the
other hand, the platinum concentrations in tumors were
higher after the administration of miriplatin/LPD than cis-
platin/LPD on both days. In addition, in the case of miripla-
tin/LPD, 18 § 15 and 17 § 13 g of platinum were
disposed of in tumors at day 0 and day 7, respectively,
while 9.6 § 6.0 g of was disposed of in tumors at day 0
after the administration of cisplatin/LPD, and 2.8 § 3.1 g
at day 7. These results indicate that platinum compounds
were selectively disposed of in tumors after the intra-
hepatic arterial administration of miriplatin/LPD, and
maintained in tumors longer than after the administration of
cisplatin/LPD.
In vivo antitumor activities of miriplatin, cisplatin, 
and zinostatin stimalamer suspended in LPD 
after intra-hepatic arterial administration
The growth of AH109A tumors was dose-dependently
inhibited by miriplatin/LPD, cisplatin/LPD, and zinostatin
stimalamer suspended in LPD (zinostatin stimalamer/LPD)
as shown in Table 1. Miriplatin/LPD, cisplatin/LPD, and
zinostatin stimalamer/LPD treatment resulted in a signiW-
cant reduction in the growth of AH109A tumors at a dose
of 400, 200, and 100 g/head, respectively. At these doses,
both miriplatin/LPD and cisplatin/LPD induced apparent
tumor regression with tumor growth rates of 79 § 31 and
66 § 29%, respectively. Although the decrease in body
Fig. 4 Development of apopto-
sis in AH109A cells treated with 
miriplatin/LPD and cisplatin/
LPD. a Representative DNA his-
tograms after propidium iodide 
staining. Left LPD, middle mi-
riplatin/LPD, right cisplatin/
LPD. b The number of sub-G1 
phase cells. AH109A cells were 
treated for 3 days with the indi-
cated concentrations of miripla-
tin/LPD and cisplatin/LPD. The 
population of sub-G1 cells was 
determined by Xow cytometry. 
Data are shown as the 
mean § SD of triplicates
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weight exceeded 10% in the group treated with the highest
dose of cisplatin/LPD (400 g/head), all agents inhibited
tumor growth without markedly enhancing body weight
loss, compared to treatment with LPD alone. Next, the in
vivo antitumor activity of miriplatin/LPD at the therapeutic
dose was compared with that of cisplatin/LPD and zinosta-
tin stimalamer/LPD (Table 2). Miriplatin/LPD and cis-
platin/LPD (400 g/head) treatment resulted in a signiWcant
Fig. 5 Blood supply to tumors, 
distribution of LPD, and plati-
num concentrations in rat livers. 
a Blood supply to AH109A 
tumors implanted in rat livers. 
A 100% (w/v) barium sulfate 
suspension was injected into the 
hepatic artery (right) or the por-
tal vein (left) at the volume of 
0.5 mL/head or 5.0 mL/head, 
respectively. Immediately after 
the administration, livers were 
resected, Wxed in formalin, and 
radiographed with a soft X-ray 
machine. Yellow circles indicate 
tumor sites. b Distribution of 
LPD. Miriplatin/LPD (400
g/head) was injected into the 
hepatic artery of tumor-bearing 
rats at the volume of 0.02 mL/
head. Seven days after the 
administration, resected livers 
were radiographed with a soft 
X-ray machine. Yellow circle 
indicates tumor site. c Platinum 
concentrations and amounts in 
tumor and normal liver tissues. 
Miriplatin/LPD (400 g/head) 
and cisplatin/LPD (400 g/
head) were injected into the 
hepatic artery of tumor-bearing 
rats at the volume of 0.02 mL/
head. Immediately and 7 days 
after the administration, resected 
livers were divided into tumor 
tissues (Wlled square) and 
normal liver tissues (open 
square). Tissue homogenates 
incinerated using nitric acid and 
hydrogen peroxide were dis-
solved in 4% aqua regia and 
introduced to FAAS. All results 
are given as the mean § SD 
(n =7 )
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reduction in tumor growth compared to that with LPD
alone, while the diVerence in the tumor growth rate
between LPD alone and zinostatin stimalamer/LPD (20 g/
head) did not reach a level of statistical signiWcance. In
addition, no signiWcant diVerence was found between the
untreated group and the group treated with LPD alone or
the sham-operated group. At the therapeutic dose, miripla-
tin/LPD, like cisplatin/LPD, was shown to be more active
than zinostatin stimalamer/LPD against AH109A tumors.
Formation of platinum-DNA adducts and induction 
of apoptosis in tumors
In the treatment of AH109A tumors, both miriplatin/LPD
and cisplatin/LPD caused tumor regression. To investigate
the mechanism involved, we examined the formation of
platinum-DNA adducts and induction of apoptosis in
tumors. Three days after the intra-hepatic arterial adminis-
tration of miriplatin/LPD and cisplatin/LPD (400 g/head),
61 § 52 and 6.6 § 8.7 pg of platinum were incorporated
into 1 g of DNA in AH109A tumors, respectively. The in
situ visualization of apoptosis at livers was evaluated using
terminal deoxynucleotidyl transferase-mediated dUTP-bio-
tin nick end labeling (TUNEL) by which fragmented DNA
could be speciWcally stained [39]. TUNEL stained exclu-
sively the nuclei in tumors after the treatment with miripla-
tin and cisplatin, but not with LPD alone (Fig. 6). On the
other hand, few TUNEL-positive nuclei were observed in
non-tumor regions in any groups. These results showed that
miriplatin/LPD, as well as cisplatin/LPD, generated plati-
num-DNA adducts and induced massive apoptosis selec-
tively in tumors after intra-hepatic arterial administration
when these agents exerted their in vivo antitumor activities.
Discussion
Most HCC patients with intermediate to advanced stage
tumors are not eligible for curative treatments due to poor
liver function or the presence of advanced liver disease. For
these patients, TACE is treatment option with a survival
Table 1 Dose-dependent antitumor activities of miriplatin/LPD, cisplatin/LPD, and zinostatin stimalamer/LPD after intra-hepatic arterial admin-
istration
Each agent suspended in LPD and LPD alone were injected into the hepatic artery of AH109A tumor-bearing rats at the volume of 0.02 mL/head.
Seven days later, tumor growth rates and changes in body weight were evaluated. All results are given as the mean § SD (n = 7). A Dunnett test
of the tumor growth rate or change in body weight at day 7 demonstrated a signiWcant diVerence, * P < 0.01, comparing the group treated with
LPD alone to those treated with agents
Experiment Treatment Dose (g/head) Tumor growth rate (%) Body weight 
change (%)
1 LPD 273 § 92 ¡2.2 § 2.7
Miriplatin/LPD 4 172 § 81 ¡3.6 § 3.5
40 160 § 115 ¡2.5 § 2.9
400 79 § 31* ¡4.5 § 2.0
2 LPD 204 § 62 ¡5.4 § 3.6
Cisplatin/LPD 100 200 § 72 ¡5.1 § 3.1
200 66 § 29* ¡5.5 § 1.8
400 54 § 13* ¡10.2 § 2.0*
3 LPD 206 § 46 ¡5.9 § 2.0
Zinostatin stimalamer/LPD 20 145 § 39 ¡6.0 § 2.5
40 144 § 60 ¡5.1 § 3.0
100 97 § 74* ¡8.2 § 4.2
Table 2 Antitumor activities of miriplatin/LPD, cisplatin/LPD, and
zinostatin stimalamer/LPD at the therapeutic dose
Each agent suspended in LPD and LPD alone were injected into the
hepatic artery of AH109A tumor-bearing rats at the volume of
0.02 mL/head. Seven days later, tumor growth rates and changes in
body weight were evaluated. No agent was administered in the untreat-
ed group (only measurement of tumor size) or sham-operated group
(measurement of tumor size and occlusion of the gastroduodenal
artery). All results are given as the mean § SD (n = 7). A Dunnett test
of the tumor growth rate or change in body weight at day 7 demon-
strated a signiWcant diVerence, * P < 0.01, comparing the group treated
with LPD alone to those treated with agents
Treatment Dose 
(g/head)
Tumor 
growth rate (%)
Body weight 
change (%)
Untreated 213 § 29 ¡2.8 § 7.3
Sham-operated 202 § 106 ¡1.2 § 2.1
LPD 185 § 37 ¡3.1 § 3.2
Miriplatin/LPD 400 67 § 24* ¡2.9 § 1.9
Cisplatin/LPD 400 33 § 23* ¡4.7 § 4.3
Zinostatin 
stimalamer/LPD
20 175 § 31 ¡1.9 § 1.7Cancer Chemother Pharmacol (2009) 64:473–483 481
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beneWt. Actually, recent randomized controlled trials
indicated that TACE induced marked objective responses
and improved the survival of selected patients with HCC
[23, 40]. Antitumor agents used for TACE should be solu-
ble or easily suspended in LPD, be stable in LPD, and be
gradually released in the tumor. However, few antitumor
agents currently available have such properties. The strat-
egy to improve the impact of TACE on survival and to
reduce systemic toxicity should be based on the develop-
ment of new agents which utilize LPD as a solvent and car-
rier. Miriplatin containing myristates as leaving groups to
improve lipophilicity was chemically designed to be a more
suitable antitumor agent for TACE [18]. Some platinum
compounds released from miriplatin/LPD, but not miripla-
tin itself, showed antitumor activities in vitro by generating
platinum-DNA adducts and inducing apoptosis. Tetrapla-
tin, oxaliplatin, NDDP, and malonatoplatin have diamino-
cyclohexane as a carrier ligand. All of these platinum
complexes undergo a transient conversion to DPC in physi-
ological surroundings because their leaving groups are eas-
ily displaced by chlorides which are abundant biological
nucleophiles [24, 25, 41, 42]. DPC was also detected as a
major platinum compound released into saline and Earle’s
balanced salt solution from miriplatin/LPD [28], indicating
that chlorides could displace leaving groups of miriplatin at
the concentrations which occurred in the culture medium or
serum. DPIC and DPI were also observed as released plati-
num compounds, suggesting that leaving groups were also
displaced by iodides from LPD, which consists of ethyl
esters of iodized poppy seed oil. In addition, DPC was as
potent as cisplatin in inhibiting the growth of hepatic cancer
cell lines. From these Wndings, it was suggested that miripl-
atin/LPD exhibited in vitro antitumor activity by releasing
platinum compounds, and DPC is one of the most likely
candidates as described by Kishimoto et al. [28]. This was
supported by the Wndings that miriplatin/LPD as well as
cisplatin/LPD formed platinum-DNA adducts and induced
apoptosis in AH109A cells.
Cisplatin has been used widely for systemic chemother-
apy for various malignancies. Although no systemic che-
motherapy using a single antitumor agent produced a
response rate of more than 10%, cisplatin was relatively
eVective against HCC [43]. Shibata et al. has reported that
the survival was signiWcantly longer in patients treated with
cisplatin/LPD as compared with those treated with LPD
containing neocarzinostatin, an active component of zinost-
atin stimalamer [17]. While cisplatin/LPD are not easy to
prepare under sterilized conditions and physically stable
[44], miriplatin is easily suspended in LPD with just mild
shaking by hand, and releases active platinum compounds
gradually [27,  28]. Based on these characteristics, it is
expected that the pharmacokinetics in livers containing
tumors after the intra-hepatic administration of miriplatin/
LPD could be improved compared with that after the
administration of cisplatin/LPD. Actually, in a rat hepatic
tumor model administered miriplatin/LPD, platinum com-
pounds were selectively disposed of at higher concentra-
tions in tumors than in non-tumor regions and maintained
in tumors longer than those released from cisplatin/LPD.
After intra-hepatic arterial administration of 14C-miripaltin/
LPD in dogs, unchanged miriplatin was the major compo-
nent retained in the liver for a long period [34]. Accord-
ingly, it was suggested that by utilizing LPD as a carrier
solvent, unchanged miriplatin was selectively disposed of
and retained for a long time in tumors. To conWrm whether
the selective and long-lasting disposition in tumors contrib-
utes to the in vivo eYcacy, antitumor activities of miripla-
tin/LPD were compared with those of cisplatin/LPD. Like
Fig. 6 TUNEL staining of rat 
livers bearing tumors. Miripla-
tin/LPD (400 g/head), cis-
platin/LPD (400 g/head), and 
LPD alone were injected into the 
hepatic artery of tumor-bearing 
rats at the volume of 0.02 mL/
head. Three days after the 
administration, livers were 
resected and Wxed in formalin. 
ParaYn sections of livers were 
stained by the TUNEL method 
and counter-stained with hema-
toxylin. Left upper untreated, 
right upper LPD alone, left 
lower miriplatin/LPD, right 
lower cisplatin/LPD. Yellow 
circles indicate tumor sites482 Cancer Chemother Pharmacol (2009) 64:473–483
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cisplatin/LPD, miriplatin/LPD was quite eVective against
AH109A tumors at the doses where severe body weight
loss was not observed. In addition, the formation of plati-
num-DNA adducts and massive apoptosis were induced
selectively in tumors treated with miriplatin/LPD as well as
cisplatin/LPD. Although we could not determine which
platinum compounds were active at tumor sites after miripl-
atin treatment, it appears that some of the platinum com-
pounds released, in which leaving groups of miriplatin were
displaced by biological nucleophiles, most probably chlo-
rides, contribute to the in vivo activities of miriplatin
because miriplatin showed a mode of action common to
most antitumor platinum complexes including cisplatin in
vivo.
The volume of LPD suspension administered in TACE is
decided according to the size of the tumor, the condition of
the tumor vessels, and the degree of liver dysfunction, and
the injection is discontinued when full accumulation of the
suspension in the tumor vessels is obtained under Xuoro-
scopic monitoring. As it is thought that the eYcacy of an
antitumor agent depends on its concentration in LPD, we
compared the in vivo antitumor activity between three
agents at the therapeutic dose. Under such conditions,
miriplatin/LPD and cisplatin/LPD (400 g/head, 20 mg/mL
in LPD), but not zinostatin stimalamer/LPD (20 g/head,
1 mg/mL), caused apparent tumor regression. At a dose
Wvefold higher than the therapeutic one, zinostatin stimal-
amer/LPD had a signiWcant growth inhibitory eVect on
AH109A tumors. Based on the growth and histological
examination of VX2 tumors implanted in rabbit livers,
remarkable antitumor activities have been observed with
zinostatin stimalamer/LPD at the therapeutic dose [45, 46].
The diVerences in the type of tumor implanted and dosing
volume might inXuence the antitumor eVect of zinostatin
stimalamer/LPD. LPD by itself induced neither growth
inhibition nor apoptosis in AH109A tumors. These results
suggested that the cytotoxicity at the tumor site after the
administration of miriplatin/LPD was resulted from the
eVect of miriplatin, and was not caused by either antiprolif-
erative eVects or vascular damage due to LPD.
In this study, it was suggested that after intra-hepatic
arterial administration, miriplatin/LPD was selectively
removed and retained for a long time in the tumor, and then
released active platinum compound(s) gradually at the
tumor site where massive apoptosis was induced after plati-
num-DNA adducts had formed. At the therapeutic dose,
miriplatin/LPD as well as cisplatin/LPD was shown to be
more active than zinostatin stimalamer/LPD against
AH109A tumors after a single intra-hepatic arterial admin-
istration without enhancing body weight loss. Our results
suggest miriplatin to be a suitable candidate for use in
TACE. To conWrm whether miriplatin was active against
human HCC, additional studies are needed in which miripl-
atin/LPD is administered into the hepatic artery of animals
bearing human hepatic tumors.
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